Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

SAN DIEGO, Dec. 17 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced preliminary results from a planned interim analysis of data at four weeks for the first dose cohort, 200 mg bid, in an ongoing Phase II study of ANA598 in combination with pegylated interferon and ribavirin (SOC) in HCV patients. 56% of patients receiving ANA598 plus SOC achieved undetectable levels of virus (<15 IU/ml) at week 4, known as Rapid Virological Response or RVR, compared to 20% of patients receiving placebo plus SOC.

ANA598 was well tolerated through four weeks, with no serious adverse events reported. An independent Data Monitoring Committee (DMC) has endorsed escalating to the second dose level, 400 mg bid, and this cohort is now open for enrollment. Anadys expects to initiate dosing in this cohort in January 2010.

"We are very pleased with the 4-week antiviral response and safety for this first dose cohort," said Steve Worland, Ph.D., President and CEO. "We look forward to the upcoming 12-week data, including antiviral response known as cEVR, for the 200 mg bid cohort in the first quarter of 2010 as well as RVR and cEVR data for the 400 mg bid cohort in the second quarter of 2010. With this additional data and results of subsequent trials, we hope to see ANA598 established as the leading non-nucleoside in HCV, suitable for combination with current standard of care as well as with other direct antivirals currently in development."

"This first Phase II data clearly demonstrates the ability of ANA598 to improve antiviral response at week 4 above what is seen with current standard of care alone," said James L. Freddo, M.D., Senior Vice President, Drug Development and Chief Medical Officer. "The RVR rate combined with a good safety and tolerability profile to date is
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 2015 Microbrush International, a leading developer, producer ... restorative procedures, today announced the acquisition of DentiSmart ... sectional matrix system used in dental restorative procedures. ... opportunity to add DentiSmart to our growing portfolio ... VP and General Manager of Microbrush. "DentiSmart,s products ...
(Date:5/4/2015)... May 4, 2015 DePuy Synthes CMF* today ... the first commercially available biosynthesized dural replacement derived from ... a part of the DePuy Synthes Companies of Johnson ... membrane that covers and protects the brain and spinal ... allow surgeons to access the brain. A dural graft, ...
(Date:5/4/2015)... Former NASA scientist Tamim Hamid ... he discussed Theradome™, the first portable and wearable OTC ... shows firsthand how, via laser technology, Theradome™ offers individuals ... will not require surgery or medication.  ... of the hair follicle, which is where the stem ...
Breaking Medicine Technology:Microbrush International Announces Acquisition of DentiSmart 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 2DePuy Synthes CMF Launches First Biosynthesized Cellulose-Based Dural Replacement For Neurosurgery 3FOX News Features Theradome as the Take-Home Solution to Tackle Baldness 2
(Date:5/4/2015)... “ LiveSchool ” was featured on ... a look at the latest and coolest applications on ... the host of AppWatch and technology expert, conducted the ... allows teachers to reward students with good behavior. , ... in the classroom. And the good people at ...
(Date:5/4/2015)... The opportunity for children to dream of ... motivating forces behind The Fairy Godmother Next Door, a new ... L. Stark. , The inspiration for the enchanting story of ... from Stark’s desire to be a fairy godmother. , “My ... to my neighbors’ children since they were born. We discuss ...
(Date:5/4/2015)... The U.S. healthcare worker shortage crisis is expected ... senior citizens (1) and 27 million Obamacare-insured Americans (2) ... Additionally, as older healthcare employees retire, there will be ... Census Bureau, the number of American workers 65 and ... those 25 to 54 will likely increase 2%. (3) ...
(Date:5/4/2015)... City, OK and Seattle, WA (PRWEB) May 04, 2015 ... announced the formation of a collaboration to facilitate development ... number of ophthalmic disorders that lead to blindness, including ... to the MiDROPS™ formulation platform developed by EyeCRO, which ... the eye via a topical eyedrop. , Under ...
(Date:5/4/2015)... New findings released today from a poll conducted ... people diagnosed with a brain tumor needed more information ... at the time of diagnosis, and had only a ... course of treatment. The release of these findings corresponds ... volunteer network, the ABTA CommYOUnity™, dedicated to serving the ...
Breaking Medicine News(10 mins):Health News:An Application for Teachers to Reward Students with Good Behavior Was Featured on NewsWatch Television 2Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 2Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 3Health News:U.S. Healthcare Worker Shortage Escalating: Sterling Warns Medical Practitioners to Rapidly Reverse Low Employee Retention 4Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 2Health News:EyeCRO and NeuMedics Announce Collaboration to Utilize MiDROPS™ Technology for the Development of NM108 3Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3
... , FRIDAY, March 2 (HealthDay News) -- Preemies face a ... British research suggests that the degree to which a child,s ... the child was. Those born between the 32nd and ... health issues than those born slightly later in the 37th ...
... , FRIDAY, March 2 (HealthDay News) -- When ... very premature deliveries, obstetricians are strongly influenced by parents, ... to save their baby,s life, a new study finds. ... 22 weeks and 26 weeks gestation (also known as ...
... A scientific method paper and video by Loyola researchers ... technique used to study some aspects of mitochondrial dysfunctions ... It has been accessed by more than 14,000 scientists ... Journal of Visualized Experiments , a peer-reviewed, PubMed-indexed ...
... FRIDAY, March 2 (HealthDay News) -- Women become less likely ... first year of college, new research finds. Declining condom ... had worse grades and who came from poorer backgrounds. ... unplanned pregnancies and sexually transmitted diseases, yet there has been ...
... HealthDay Reporter , FRIDAY, March 2 (HealthDay News) ... high blood pressure, diabetes and other chronic conditions can have ... choices exist for some types of drugs, adjusting medications is ... pharmacy officer with the Harris County Hospital District, in Houston. ...
... FRIDAY, March 2 (HealthDay News) -- The social networking ... platform for derogatory comments about epilepsy and seizures, researchers ... issue of Epilepsy and Behavior , Canadian researchers ... of them as offensive. The study authors pointed out ...
Cached Medicine News:Health News:Timing of Preemie Birth May Be Key to Kids' Health Later 2Health News:Parents' Wishes Sway Docs' Choices on Preterm Deliveries 2Health News:Video publication goes viral 2Health News:College Women's Condom Use Falls in Freshman Year 2Health News:Prescription Meds Can Put on Unwanted Pounds 2Health News:Prescription Meds Can Put on Unwanted Pounds 3Health News:Twitter Adding to Stigma of Epilepsy, Study Says 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: